Why Equitable Trial Design, Regulatory Readiness, and Multidisciplinary Strategy Begin with Education

Africa carries 25% of the global disease burden yet hosted only 1.1% of global clinical trials in 2023 (Iyer, 2025). This disparity reflects a deeper imbalance in how clinical trials are designed, where they are activated, and who benefits from emerging therapies.

The GMDP Academy’s Certification in Medicines Development (CMD) provides professionals with the tools and frameworks to better understand and navigate the systemic challenges contributing to this imbalance. Through its globally aligned, modular training program, CMD equips learners with the scientific, ethical, operational, and regulatory knowledge to lead inclusive, effective, and patient-centered clinical development.

🌍 The Challenge: Structural Barriers to Equity

According to a 2024 study in BMJ Global Health, trials in sub-Saharan Africa face steep administrative hurdles, with non-COVID studies taking an average of 259 days to activate, compared to 80 days for COVID-related trials (Saleh et al., 2024). This lag is due to siloed regulatory systems, sequential ethics reviews, and a lack of harmonization—all of which discourage sponsors from including African sites in global trials.

Exclusion isn’t just operationally inefficient—it’s ethically fraught. It delays access to life-saving innovations, undermines the generalizability of trial results, and reinforces historical inequities in global health.

🎓 The CMD Program: A Comprehensive Solution

The Certification in Medicines Development is designed to prepare professionals across the full lifecycle of drug development—from early discovery to post-marketing strategy. The curriculum includes eight interdisciplinary modules, each aligned with IFAPP/PharmaTrain global competency standards.

The GMDP Academy’s Certification in Medicines Development (CMD) provides professionals with the tools and frameworks to better understand and navigate the systemic challenges contributing to this imbalance.

Participants learn to:

  • Design clinical trials that account for diverse geographies and populations
  • Navigate regulatory complexity, including parallel vs. sequential review systems
  • Apply ethical reasoning to cross-border and multidisciplinary team challenges
  • Translate scientific findings into policy, access, and health system relevance
  • Collaborate across functions—from Clinical Operations to Medical Affairs, Regulatory Affairs to Pharmacovigilance

🔍 Modules That Address Real-World Barriers

  • Module 3: Drug Discovery and Development explores the foundational science and trial design principles needed to identify inclusive research questions.
  • Module 4: Clinical Trials dives into feasibility, protocol development, and navigating site and regulatory environments across regions.
  • Module 6: Medical Affairs as a Strategic Business Partner empowers learners to build partnerships with local institutions, patient groups, and global stakeholders.
  • Modules 2 and 7 cover health economics, leadership, and ethical governance—critical to making research both sustainable and community-aligned.

Together, these modules create a 360° understanding of the clinical development landscape—essential for professionals working across both high- and low-resource settings.

🛠️ Moving from Inclusion Rhetoric to Infrastructure

The CMD program not only educates individuals but also contributes to system-wide change. By training professionals from or working in low- and middle-income countries (LMICs), the program helps build capacity for:

  • Faster, better coordinated trial activation
  • Local leadership in protocol design and ethics review
  • Data generation that informs global regulatory and reimbursement decisions
  • Sustainable research partnerships that endure beyond a single study

As the WHO and African Medicines Agency move toward regulatory harmonization, CMD graduates will be well-positioned to lead the next generation of globally relevant, ethically grounded trials.

📅 Join the Movement for Equitable Research

GMDP Academy’s CMD program is more than a certification—it’s a call to action for scientific leadership, global inclusivity, and lifelong learning.

🔗 Learn more and apply: https://gmdpacademy.org/certification-programs/certification-in-medicines-development/
 📬 Questions? Contact: admissions@gmdpacademy.org

📚 References

Iyer, J. K. (2025, July 9). Improving access to innovative medicines in Africa starts with clinical trials. World Economic Forum. https://www.weforum.org/stories/2025/07/healthcare-access-africa-clinical-trials/Saleh, M., Sharma, K., Shamshudin, A., Obayo, I., Gondi, S., & Karimi, N. (2024). Regulatory approval of clinical trials: Is it time to reinvent the wheel? BMJ Global Health, 9(1), e013727. https://doi.org/10.1136/bmjgh-2023-013727

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred